Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Elixir Department: SOP for Avoiding Cross-Contamination During Manufacturing – V 2.0

Posted on By

Elixir Department: SOP for Avoiding Cross-Contamination During Manufacturing – V 2.0

Standard Operating Procedure for Avoiding Cross-Contamination During Elixir Manufacturing

Department Elixir Department
SOP No. SOP/ELX/087/2025
Supersedes SOP/ELX/087/2022
Page No. Page 1 of 8
Issue Date 11/04/2025
Effective Date 15/04/2025
Review Date 11/04/2026

1. Purpose

To define procedures and preventive measures to eliminate cross-contamination risks during the manufacturing of elixir products and to ensure compliance with GMP guidelines.

2. Scope

This SOP is applicable to all manufacturing activities within the Elixir Department where there is a risk of contamination due to shared equipment, personnel movement, air handling, and material transfers.

3. Responsibilities

  • Production Operator:
    • Follow defined gowning, cleaning, and equipment segregation procedures.
    • Report any potential contamination events immediately.
  • Production Supervisor:
    • Ensure proper scheduling and line clearance between batches.
    • Verify cleaning effectiveness and approve use of shared areas.
  • QA Officer:
    • Conduct environmental monitoring and audit adherence to contamination control practices.

See also  Elixir Department: SOP for Detergent Solution Preparation for Cleaning - V 2.0

4. Accountability

The Head of Production is accountable for implementation and periodic review of contamination control strategies and for ensuring corrective actions are implemented if risks are identified.

5. Procedure

5.1 Environmental and Facility Controls

  1. Manufacturing areas must be segregated by physical barriers, pressure differentials, or dedicated rooms where feasible.
  2. Maintain proper air filtration (HEPA filters) and HVAC zoning as per cleanroom classification.
  3. Perform cleaning of floors, walls, and surfaces after each batch or product changeover using validated disinfectants.

5.2 Personnel and Gowning

  1. Use dedicated cleanroom garments and accessories for each room.
  2. Follow gowning SOPs strictly and avoid personnel movement between manufacturing areas without gown change.
  3. Limit number of personnel in process areas as per defined occupancy limits.

5.3 Equipment Cleaning and Segregation

  1. Use dedicated or properly cleaned and sanitized equipment for each product.
  2. Perform line clearance and cleaning verification before initiating new batch processing.
  3. Use separate transfer lines and fittings where product nature demands (e.g., alcohol-based vs aqueous-based elixirs).
See also  Elixir Department: SOP for Dispensing Humidity Sensitive Materials - V 2.0

5.4 Material Handling

  1. Label all materials clearly with product name, batch number, and status (e.g., Approved, Quarantined).
  2. Transport materials in closed containers and along defined material movement routes.
  3. Do not store different product intermediates in the same tank or holding area.

5.5 Scheduling and Campaigning

  1. Where feasible, schedule manufacturing in campaigns of similar products to reduce changeovers.
  2. Avoid simultaneous processing of incompatible or high-risk products within the same room.

5.6 Deviation and Incident Handling

  1. Any suspected cross-contamination must be reported immediately to QA.
  2. Initiate deviation report and investigate with potential root cause analysis.
  3. Take corrective and preventive actions (CAPA) before restarting operations.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • CAPA: Corrective and Preventive Action
  • HVAC: Heating, Ventilation, and Air Conditioning

7. Documents

  1. Contamination Risk Assessment Log (Annexure-1)
  2. Cleaning Verification Record (Annexure-2)
  3. Deviation Report Form
See also  Elixir Department: SOP for Sampling of Raw Materials for Elixirs - V 2.0

8. References

  • 21 CFR Part 211.113 – Control of Microbiological Contamination
  • WHO TRS 986 – GMP for Pharmaceuticals
  • ICH Q9 – Quality Risk Management

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Contamination Risk Assessment Log

Date Batch No. Risk Identified Preventive Action Operator QA Verified
11/04/2025 ELX-1026 Residual alcohol vapors Delayed next batch by 2 hrs Rajesh Kumar Sunita Reddy

Annexure-2: Cleaning Verification Record

Equipment ID Previous Product Cleaning Date Swab Test Result Verified By Status
MX-04 Multivitamin Elixir 10/04/2025 Pass QA Analyst Ready for Use

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial SOP Release New SOP QA Head
11/04/2025 2.0 Added preventive measures and monitoring logs Audit Observation QA Head
Elixers V 2.0 Tags:Elixir colorants, Elixir dosage form, Elixir filtration techniques, Elixir flavoring agents, Elixir formulation, Elixir GMP compliance, Elixir manufacturing process, Elixir manufacturing SOPs, Elixir packaging requirements, Elixir pharmacopoeial standards, Elixir preparation methods, Elixir preservatives, Elixir production equipment, Elixir quality control, Elixir regulatory guidelines, Elixir shelf life, Elixir stability testing, Elixir sterilization methods, Elixir storage conditions, Elixir sweetening agents, Elixir viscosity modifiers, Hydroalcoholic solutions, Medicated elixirs, Non-medicated elixirs, Pharmaceutical elixirs

Post navigation

Previous Post: API Manufacturing: SOP for Change Control Request Evaluation and Implementation – V 2.0
Next Post: Gel Manufacturing: SOP for Equipment Swab Testing for Cleaning Effectiveness – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version